Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-12-11
2007-12-11
Wilson, Michael C. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093210
Reexamination Certificate
active
10940358
ABSTRACT:
A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.
REFERENCES:
patent: 5662896 (1997-09-01), Barber et al.
patent: 6013638 (2000-01-01), Crystal et al.
patent: 6297219 (2001-10-01), Nabel et al.
patent: 0185573 (1986-06-01), None
patent: 2 688 514 (1992-03-01), None
patent: WO 88/00971 (1988-02-01), None
patent: 93/19191 (1993-09-01), None
Miller (1995, FASEB J., vol. 9, pp. 190-199).
Deonarain (1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69).
Verma (Sep. 1997, Nature, vol. 389, pp. 239-242).
Crystal (1995, Science, vol. 270, pp. 404-410).
Rosenfeld, 1991, Science, vol. 252, pp. 431-434.
Colicos (Carcinogenesis, 1991, vol. 12, No. 2, p. 249-255).
Gorman (PNAS, Nov. 1982, vol. 79, p. 6777-6781).
Wilkinson (Nucleic Acids Res., 1992, vol. 20, No. 9, p. 2233-2239).
Lebovitz, et al., Parvovirus H-1 Expression: Mapping of the Abundant Cytroplasmic Transcripts and Identification of Promoter Sties and Overlapping Transcription Units, May 1986, Journal of Virology, vol. 58 No. 2 pp. 271-280.
Gum et al., Parvovirus H-1 Promoter Requires the trans-Activation Region (tar), and SP1 site, and a TATA Box for Full Activity, 1992, Virology, 187 pp. 10-17.
Miller, et al., Targeted vectors for gene therapy, 1995, FASEB, vol. 9, pp. 190-199.
Deonarain, Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents, vol. 8, pp. 53-69.
Verma, et al., Gene therapy-promises, problems and prospects, 1997, NATURE, vol. 389, pp. 239-242.
Crystal, Transfer of genes to humans: Early lessons and obstacles to success, 1995, Science, vol. 270, pp. 404-410.
Gluzman et al., Exhausted Vinyl Vectors, pp. 187-192 (1982).
Gratham, F.L. et al.,J. Gen. Virol., 36:59-72 (1977).
Quantin et al., “Adenovirus as an Expression Vector in muscle Cells Application to Dystrophin”,Collogue Inserm, (Human Gene Transfer, International Workshop, Paris, France), 219:271-272 (Apr. 11, 1991).
Rosenfeld et al., “Adenovirus-mediated Transfer of a Recombinant Alpha-alntitrypsin Gene to the Lung Epithelium In Vivo”,Science, 252(5004):431-434 (Apr. 19, 1991).
Russell, S.J., “Lymphokine Gene Therapy for Cancer”,Immunology Today, 11(6):196-200 (Jun. 1990).
Rosenberg, S. et al., “A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone,”The New England Journal of Medicine, 316(15):889-896 (Apr. 9, 1987).
Singh, S. et al., “Up-Regulation by Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) of Induction of Lymphokine (IL-2)-Activated Killer (LAK) Cells by Human Blood Monoctyes,”Int. J. Cancer, 44:170-176 (1989).
Israel, D. et al., “Highly inducible expression from vectors containing multiple GRE's in CHO cells over expressing the glucocorticoid receptor,”Nucleic Acids Res., 17(12):4589-4604 (Jun. 26, 1989) (Abstract only).
Wilkinson, G. et al., “Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector”,Nucleic Acids Research, 20(9):2233-2239 (1992).
Colicos, M. et al., “Construction of a recombinant adenovirus containing the denV gene from bacteriophase T4 which can partially restore the DNA repair deficiency in xeroderma pigmentosum fibroblasts”,Carcinogenesis, 12(2):249-255 (Feb. 1991) (Abstract only).
Squiban, P., “France. Transgene Announces Progress in Cancer Clinical Development Programs”,TCLine News, May 14, 2003 (3 pages).
Squiban, P., “Transgene Presents Positive Phase I/II Data on its Adeno-Interferon Gamma Product in Cutaneous Lymphoma at the American Society of Gene Therapy Meeting”,TCLine News, Jun. 11, 2003 (2 pages).
Addison, C. et al., “Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model”,Proc. Natl. Acad. Sci. USA, 92:8522-8526 (Aug. 1995).
Schmidt-Wolf, G. et al., “Cytokines and clinical gene therapy”,Eur. J. Immunol., 25:1137-1140 (1995).
Clark, I. et al., “Roles of TNF in malaria and other parasitic infections”,Immunology Series, 56:365-407 (1992) Medline Accession No. 92199019 (Abstract only).
Ovington, K. et al., “Cytokines and immunological control of Elmeria spp.”,International Journal for Parasitology, 25(11):1331-51 (Nov. 1995) Medline Accession No. 96229273 (Abstract only).
Brunda, M. J., “Interleukin-12”,Journal of Leukocyte Biology, 56(2):280-288 (Feb. 1994) Medline Accession No. 94132739 (Abstract only).
Stratford-Perricaudet, et al., “Gene Transfer into Animals: The Promise of Adenovirus”,Collogue Inserm, (Human Gene Transfer, International Workshop, Paris, France), 219:51-61 (Apr. 11, 1991).
Venkatesh et al., “Selective Induction of Toxicity to Human Cells Expressing Human Immunodeficiency Virus Type I Tat by a Conditionally Cytotoxic Adenovirus Vector”,Proceedings of the National Academy of Sciences of USA, 87(22):8746-8750 (Nov. 1990).
Wilkinson, GWG et al., “Constitutive and Enhanced Expression from the CMV Major IE Promoter in a Defective Adenovirus Vector”,Nucleic Acids Research, 20(9):2233-2239 (May 11, 1992).
Bramson et al., Direct Intratumoral Injection of an Adenovirus Expressing Interleukin-12 Induces Regression and Long-Lasting Immunity That is Associated with Highly Localized Expression of Interleukin-12, Human Gene Therapy 7:1995-2002 (1996).
Cordier et al., Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene, Gene Therapy, 2:16-21 (1996).
Gambotto et al., Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12, Cancer Gene Therapy, vol. 6, No. 1, pp. 45-53 (1999).
Huang et al., Gene therapy for hepatocellular carcinoma: long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo, Gene Therapy, 3(11):980-7 (1996).
Leroy et al., Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes, Res. Immunol., 149:681-684 (1998).
Stewart et al., Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial, Gene Therapy, 6:350-363 (1999).
Toloza et al., Transduction of murine and human tumors using recombinant adenovirus vectors, Ann. Surg. Oncol., 4(1):70-9, (1997).
Tursz et al., Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients, J. Natl. Cancer Inst., 88(24):1857-63 (1996).
Zhang et al., Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy, Proc. Natl. Acad. Sci., 93(9):4513-8 (1996).
Slos, P. et al., “Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: Induction of CD8+ T-cell immunity and NK activity”,Cancer Gene Therapy, vol. 8, No. 5, pp. 321-332 (2001).
Ahmed, C., et al. “In Vivo Tumor Suppression by Adenovirus-Mediated Interferon α2b Gene Delivery”,Human Gene Therapy, vol. 10, pp. 77-84 (Jan. 1, 1999).
Fujii, S., et al. “Activated Dendritic Cells From Bone Marrow Cells of Mice Receiving Cytokine-Expressing Tumor Cells Are Associated With the Enhanced Survival of Mice Bearing Syngeneic Tumors”,Blood, vol. 93, No. 12, pp. 4328-4335 (Jun. 15, 1999).
Graham, F., “Undercurrents: Adenoviruses as expression vectors and recombinant vaccines,”Tibtech, 8:85-87.
Haddada Hedi Mohamed
Perricaudet Michel
Ragot Thierry
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Merchant & Gould P.C.
Wilson Michael C.
LandOfFree
Defective recombinant adenoviruses expressing cytokines for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Defective recombinant adenoviruses expressing cytokines for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Defective recombinant adenoviruses expressing cytokines for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3898346